A 52-year-old obese woman (BMI 33 kg/m²) with osteoarthritis asks about weight loss options. She has tried lifestyle changes with minimal success. Whi...

Question

A 52-year-old obese woman (BMI 33 kg/m²) with osteoarthritis asks about weight loss options. She has tried lifestyle changes with minimal success. Which pharmacological option is currently recommended adjunct to lifestyle modification for obesity management in Australia?

Accepted Answer

GLP-1 receptor agonist (e.g. semaglutide) where PBS criteria are met

Answer

Long-term phentermine monotherapy

Answer

Orlistat as first-line for all patients

Answer

Very low-calorie diet shakes only

Answer

No pharmacological options are available

au-amc MCQ (SBA): Obesity pharmacotherapy

A 52-year-old obese woman (BMI 33 kg/m²) with osteoarthritis asks about weight loss options. She has tried lifestyle changes with minimal success. Which pharmacological option is currently recommended adjunct to lifestyle modification for obesity management in Australia?